Biopharmaceutical CMO And CRO Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Biopharmaceutical CMO And CRO Market Trends and Insights

Expanding Biologics And Biosimilars Pipeline

The FDA cleared 59 novel drugs in 2024 and another 18 biosimilars in 2025 under streamlined interchangeability rules, pulling analytical and process-development work toward external partners. Monoclonal-antibody pipelines climbed 18% year-on-year, extending into rare-disease combinations that require co-formulation know-how. Cell and gene therapy programs surpassed 2,000 globally, with roughly 80% already contracting CDMOs for early process optimisation to secure late-stage slots. WHO now lists 34 national authorities at Maturity Level 3 or higher, broadening where pivotal biosimilar studies can run.^{[2]Dr. Soumya Swaminathan, “Global Benchmarking Tool: List of Maturity-Level-3 National Regulatory Authorities,” World Health Organization, who.int} India’s vaccine self-sufficiency hit 99%, and China reached roughly 90%, enabling local CDMOs to compete on both cost and speed for biosimilar tech-transfer projects.^{[3]Dr. Renu Swarup, “India and China Reach Near Self-Sufficiency in Vaccine Manufacturing,” World Health Organization, who.int}

Outsourcing Shift From Small To Large Molecules

Small-molecule API outsourcing hit 87% in 2024, essentially topping out, whereas biologics API outsourcing lagged at 61%, pointing to a structural headroom sponsors are rushing to close. Finished-dose outsourcing reached 61% versus a decade average of 50% as innovators reuse in-house lines for high-margin modalities. Large biopharma pledged USD 370 billion in U.S. plants yet earmarked most of that spend for proprietary drug-substance assets, leaving drug-product and clinical supplies to external partners. Facilities such as Lilly’s USD 3.5 billion Pennsylvania site and Novo Nordisk’s USD 4.1 billion Clayton plant show innovators keeping high-volume commercial assets internal while outsourcing early and niche programs. Single-use technology now allows CDMOs to flip between products within days, making large-molecule contract production economical at sub-large-batch volumes.

Cost & Time Pressure On Late-Stage Trials

Half of global clinical development spend increases as outsourcing approaches 70% penetration. ICON plc reported a USD 15.5 billion backlog with 51% executable inside 12 months, and hit more than 90% of milestones early or on time. Sponsors now pay premiums for predictability because Phase III study timelines exceed 24 months across many indications. IQVIA’s alliance with Duke Clinical Research Institute, formed in 2026, targets obesity and cardiometabolic trials, underscoring CRO expansion into data-rich therapeutic areas. Functional-service outsourcing embeds CRO talent within sponsor teams, accelerating protocol amendments and compressing cycle times.

Single-Use Bioprocessing Economics

Single-use bioreactors topped 70% of CMO installations in 2024 and should hold that level through 2028 due to capex savings that exceed 40% versus stainless steel. Fujifilm Diosynth’s USD 928 million Denmark expansion doubles capacity and layers in fill-finish lines designed for disposable upstream trains. WuXi Biologics' USD 1.4 billion Singapore site completed Asia’s first commercial three-by-5,000 L single-use PPQ run in 2025, validating the scale potential of disposable technology. Modular cleanrooms and pre-validated skids shrink build-outs from 36 months to under 24, vital as expedited approvals advance launch dates by up to 18 months. Life-cycle analyses now show lower total carbon versus steam-cleaned stainless lines once energy and water savings.

Viral-Vector Capacity Bottlenecks

Lead times run 12-18 months for GMP AAV slots, forcing sponsors to pre-book during Phase I and absorb cancellation penalties if programs falter. EU GMP Annex 1, in force since 2023, mandates isolator-based aseptic processing and real-time particulate tracking, raising capex hurdles. Lotte Biologics’ USD 3.3 billion Songdo antibody-drug conjugate site shows the capital shift, yet vector suites need bespoke air handling and waste neutralisation that cannot be retrofitted easily. More than 2,000 CGT programs were active in 2024, but only a handful of plants can scale autologous CAR-T therapies, creating a structural mismatch. FDA issued 561 Form 483s in 2024 and over 600 in 2025, many tied to aseptic deviations, underscoring quality barriers that slow capacity growth.

Regulatory Harmonisation Gaps

ICH guidelines exist, yet biosimilar bridging study demands diverge, adding 6-12 months to launches. FDA’s 2024 pathway trims trial loads for interchangeables, while EMA still insists on head-to-head immunogenicity work for some classes. Japan’s PMDA requires local pharmacokinetics irrespective of U.S./EU data, and China’s reforms cut IND timelines by up to 70% but leave data-integrity rules opaque. Africa hosts just 34 regulators at WHO Maturity Level 3 or higher, limiting sites for pivotal biosimilar studies. Latin America scores 59% on FIFARMA’s 2025 research-climate index, with trial density below 30 per million residents, far behind South Korea’s 300-plus.

Segment Analysis

By Service Type: CMOs Hold The Revenue Anchor While CROs Scale Faster

CMOs captured 57.24% of 2025 turnover, underscoring sponsor preference to outsource asset-heavy drug-substance work instead of funding depreciating capacity in-house. The biopharmaceutical CMO and CRO market share advantage nevertheless shifts when growth is considered: CRO revenue is set to climb 10.42% through 2031 as late-phase protocol complexity drives decentralised-trial adoption. Over the same horizon, the biopharmaceutical CMO and CRO market size tied to manufacturing expands steadily but cedes relative growth to data-rich study services. ICON’s USD 15.5 billion backlog, with half deliverable in 12 months, signals stable outsource budgets, while IQVIA’s 2026 collaboration with Boehringer Ingelheim shows CROs moving into real-world evidence and regulatory strategy.

Sponsors still rely on CMOs for capacity insurance: global mammalian-cell capacity is forecast to rise from about 6,750 kL in 2024 to close to 9,000 kL by 2028, and CMO share climbs from 28% to roughly 40%. Single-site giants such as Samsung Biologics’ 784 kL Incheon campus provide both drug-substance and fill-finish, reducing tech-transfer friction. Industry watchers expect CMOs to keep majority revenue, yet CROs will outpace them in percentage terms, driven by AI-enabled patient matching and real-time data capture that trims enrolment timelines by double digits.

By Biologic Type: Monoclonal Antibodies Dominate, But CGTs Lead Growth

Monoclonal antibodies held 44.57% of 2025 revenue as innovators expand into rare diseases and combination regimens needing co-formulation finesse. The segment’s absolute expansion secures the biopharmaceutical CMO and CRO market size floor; however, cell and gene therapies clock the fastest 9.37% CAGR, buoyed by over 2,000 active programs and widespread CDMO engagement during preclinical optimisation. Vaccine volumes normalised post-pandemic, but oligopolistic share keeps margins attractive: the top 10 producers controlled 85% of 2023 value.

Recombinant proteins surge on the back of GLP-1 combinations such as CagriSema, forecast for USD 15 billion sales by 2029, pressuring fill-finish lines tailored to prefilled syringes. Antibody-drug conjugates grow near 20% CAGR, yet capacity shortages endure, prompting Samsung and Lotte to earmark over USD 4 billion for dedicated suites. Sponsors view CGT outsourcing as risk mitigation; lead times, regulatory scrutiny, and bespoke analytics challenge internal build-or-buy economics, handing CDMOs a durable growth lever.

By Source System: Mammalian Platforms Retain The Lion’s Share

Mammalian expression accounted for 72.38% of 2025 revenue and should rise 8.31% annually through 2031 as CHO and HEK cells remain gold standards for glycosylated proteins. The biopharmaceutical CMO and CRO market size tied to mammalian culture is projected to swell alongside capacity build-outs such as Lonza’s six 20,000 L bioreactors that went live at Visp in 2025. Microbial platforms, while holding a smaller slice, remain indispensable for insulin and enzyme biosimilars thanks to faster batch cycles and lower media costs.

Single-use adoption favors mammalian systems: more than 70% of CMO installs in 2024 involved disposable bioreactors, sustaining turnover as tech lowers cleaning downtime. Emerging insect and plant systems stay niche, hindered by scant GMP capacity and unfamiliar regulatory paths.

Note: Segment shares of all individual segments available upon report purchase

By Scale Of Operation: Commercial Volumes Lead, Clinical Services Expand Quickly

Commercial manufacturing drove 61.39% of 2025 revenue as blockbuster antibodies and GLP-1 agonists require multi-ton output. Yet pre-clinical and clinical outsourcing is growing faster at 10.64% CAGR to 2031, a pattern evident in Aragen’s Bangalore site aimed at early-stage programs. Sponsors lock slots years ahead to dodge the 12-18-month queue now common for commercial bioreactors, pushing the biopharmaceutical CMO and CRO market share for clinical services higher by decade end.

Samsung Biologics’ Plant 5 added 180,000 L in 2025, elevating single-site capacity leadership while offering cradle-to-commercial continuity. Changeover-light single-use systems dominate clinical supply, letting CMOs pivot between client products in days.

By End User: Large Pharma Anchors Demand While Virtual Biotechs Accelerate

Large biopharma generated 67.83% of 2025 turnover through multi-year supply guarantees that finance CDMO expansions. Conversely, small and mid-size companies will grow 10.94% yearly as venture money fuels pipeline creation without parallel bricks-and-mortar investment. Lonza reports 500-plus clients leveraging its intellectual property, highlighting how CDMOs capture upside beyond fee-for-service.

Virtual biotechs may lack bargaining muscle on price, yet they entice CDMOs with novel modalities, mRNA, base editing, that can yield milestone royalties. Large-pharma onshoring investments largely focus on proprietary drug-substance assets, keeping ancillary services outsourced and sustaining dual-track growth across end-user buckets.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America held 37.81% of 2025 revenue, anchored by the United States’ dense innovator pipelines and rapid IND processing. More than USD 370 billion in announced plant spend underlines the region’s biomanufacturing primacy, from Lilly’s USD 3.5 billion Pennsylvania build to Novo Nordisk’s USD 4.1 billion GLP-1 facility. Samsung Biologics’ USD 280 million acquisition of GSK’s Rockville plant granted 60,000 L of capacity and 500 staff, exemplifying Asian CDMOs entering the U.S. for proximity to clients. Canada and Mexico contribute niche fill-finish and near-shore supply roles under free-trade frameworks.

Europe combines deep biosimilar know-how with mid-tier CDMOs specialising in ADCs and autologous cells. Annex 1 compliance raises cost bars but also forms a quality moat. Investments include Fujifilm Diosynth’s USD 928 million Denmark expansion and BioNTech’s EUR 1.8 billion Mainz mRNA hub. The biopharmaceutical CMO and CRO market size in Europe benefits from balanced demand across incumbent big pharma and specialty biotechs.

Asia-Pacific is the fastest-growing region at 8.33% CAGR through 2031. Samsung Biologics’ 784 kL campus and WuXi Biologics’ USD 1.4 billion Singapore site evidence technical parity with Western peers. China accounts for 40% of global clinical trials, yet data-integrity questions keep some pivotal studies abroad. India’s 99% vaccine self-sufficiency and Aragen’s 2025 Bangalore launch illustrate rising domestic capability. Australia and South Korea round out regional momentum with streamlined early-phase pathways.

Middle East & Africa and South America remain emerging. Africa imports over 70% of its medicines and runs production lines at 30-60% utilisation mainly due to fragmented regulation. Latin America scores 59% on research-climate metrics; Chile and Costa Rica lead but still trail Asian benchmarks by orders of magnitude. Near-term uplift hinges on harmonised regulation and targeted workforce development.